Lincomycin HCl USP 300 mg
Each ml contains:
Lincomycin HCl USP 300 mg.
LlNCOBECT is indicated in infections due to susceptible strains of streptococci, pneumococci and staphylococci. LlNCOBECT is effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to Lincomycin. Staphylococcal strains resistant to LlNCOBECT have been recovered; culture and susceptibility studies should be performed in conjunction with LlNCOBECT thereapy in the case of macrolides. Partial but not complete cross resistance may occur. The drug may be administered concomitantly with other antimicrobial agents when indicated.
DOSAGE & ADMINISTRATION:
Intramuscular- Adults: Mild to moderately severe ‘infections· 600 mg (21:’1) intramuscular every 12 hours (or more often) as determined by the severity of infection.
Children over 1 month of age: Mild to moderately severe infection. One Intramuscular injection of 10 mg/lb (5 mg/lb) every 24 hours. Severe injection. One intramuscular injection of 10 mg/kg (5 mg/lb.) every 12 hours (or more often) as determined by the severity of injection.